A Multicenter, Open-Label, Randomized Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
This research study is for teenagers who have moderate to severe plaque psoriasis, a skin condition causing red, scaly patches. The study is investigating a new medication called bimekizumab. We are running a 'Phase II' trial, which means we are exploring how different doses of bimekizumab work in the body, checking if it's safe to use, and seeing how effective it is at improving psoriasis symptoms. We will be carefully monitoring the level of the medicine in participants' blood over a long period. We'll also be looking for any side effects and observing general health changes to ensure the treatment is well-tolerated. This study is crucial for gathering more information about bimekizumab as a potential new treatment option for young people.
At a glance
What is this study about?
This study is about a new medicine called bimekizumab, designed to help teenagers with a type of psoriasis called plaque psoriasis. Psoriasis is a long-lasting skin condition that causes red, flaky, crusty patches covered with silvery scales. When it's described as 'moderate to severe', it means it affects a significant area of the body or has a major impact on someone's life.
The main goals of this research are to understand how bimekizumab acts in the body – specifically, how much of the medicine is present in the blood over time. We also want to find out if it's safe to use and whether it helps improve the skin and reduce psoriasis symptoms. By studying these things in teenagers, we hope to learn if bimekizumab could be a good treatment option for young people in the future.
This is a 'Phase II' study, which means it's an important early step in developing new medicines. We're carefully exploring how the treatment works and gathering detailed information on its safety and effects. The insights gained from this study will help us decide if bimekizumab should move forward to larger studies, bringing us closer to potentially offering another effective treatment for psoriasis.
Key takeaways
- The study is for teenagers with moderate to severe plaque psoriasis.
- It's testing a new medicine called bimekizumab.
- The main goals are to check the medicine's safety, how it works in the body, and if it improves psoriasis.
- Participation involves regular clinic visits over about two and a half years.
- You will be closely monitored by doctors and nurses.
- You can stop participating at any time.
Who may be eligible?
This study is open to both boys and girls of all ages, as long as they meet specific health requirements related to their psoriasis.
To be considered for this study, you would need to have been diagnosed with moderate to severe plaque psoriasis. This means your psoriasis affects a significant part of your body or is causing a lot of discomfort and impacting your daily life. The doctors involved in the study will check your medical history and current health carefully to make sure the study is a good fit for you.
There will be other detailed health checks to ensure it's safe for you to take part. This includes reviewing any other medical conditions you might have, and medications you are currently taking. Only those who meet all these health criteria will be able to join.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Do I have moderate to severe plaque psoriasis?
- Am I a teenager?
- Am I generally healthy apart from my psoriasis?
- Am I willing to attend regular clinic appointments for about 2.5 years?
- Am I currently taking any medications that might conflict with the study drug?
What does participation involve?
If you decide to take part in this study, you would be randomly assigned to receive one of two different doses of bimekizumab. This medicine is given as an injection. Over the course of the study, you would come in for regular visits to our clinic. These visits would involve taking blood samples to measure the level of the study medicine in your body, and having physical check-ups to monitor your overall health and any changes in your psoriasis.
We will also ask you questions about how you are feeling and if you are experiencing any side effects. Your blood pressure, heart rate, temperature, and weight will be checked regularly. These visits will happen at set times over a period of about two years, with ongoing follow-up after your last dose to ensure your continued safety. The full study may last for approximately two and a half years, including the follow-up period.
Potential risks and benefits
Locations (2)
- —UnverifiedPoland
- —UnverifiedGermany
Common questions
What is plaque psoriasis?
Plaque psoriasis is a common skin condition that causes red, scaly, and itchy patches on the skin, often on elbows, knees, scalp, and lower back.
What is bimekizumab?
Bimekizumab is a new experimental medicine being tested to see if it can help treat moderate to severe plaque psoriasis.
What does 'Phase II' mean?
Phase II means this is an early stage of research where we are exploring how well the medicine works, how safe it is, and what dose might be best, in a larger group of people than in a very first study.
How will my health be checked during the study?
Your health will be checked regularly through physical exams, blood tests, and by monitoring your vital signs, like blood pressure and heart rate.
Can I stop being part of the study once I've started?
Yes, you can choose to leave the study at any time, for any reason, and it will not affect your usual medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.